Form 8-K - Current report:
SEC Accession No. 0001493152-25-024996
Filing Date
2025-11-25
Accepted
2025-11-25 17:00:24
Documents
18
Period of Report
2025-11-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 66681
2 EX-3.1 ex3-1.htm EX-3.1 40935
3 EX-10.1 ex10-1.htm EX-10.1 256231
4 EX-10.2 ex10-2.htm EX-10.2 99667
5 EX-99.1 ex99-1.htm EX-99.1 14847
6 GRAPHIC ex99-1_001.jpg GRAPHIC 4821
  Complete submission text file 0001493152-25-024996.txt   785271

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lixt-20251125.xsd EX-101.SCH 3784
8 XBRL DEFINITION FILE lixt-20251125_def.xml EX-101.DEF 26650
9 XBRL LABEL FILE lixt-20251125_lab.xml EX-101.LAB 36768
10 XBRL PRESENTATION FILE lixt-20251125_pre.xml EX-101.PRE 25274
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5911
Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251522397
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)